- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Oxyhemoglobin.
Displaying page 1 of 1.
| EudraCT Number: 2017-000895-27 | Sponsor Protocol Number: IIBSP-OXI-2017-18 | Start Date*: 2017-07-21 |
| Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau | ||
| Full Title: Can high-flow oxygen optimize the benefits of Pulmonary Rehabilitation in patients with Diffuse Interstitial LungDisease (ILD) with oxygen desaturation during effort? | ||
| Medical condition: Diffuse Interstitial LungDisease (ILD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004334-13 | Sponsor Protocol Number: MSI-1995-203 | Start Date*: 2005-04-08 |
| Sponsor Name:Genaera Corporation | ||
| Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects | ||
| Medical condition: Cystic Fibrosis | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-005131-40 | Sponsor Protocol Number: MA29957 | Start Date*: 2016-10-20 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATH... | |||||||||||||
| Medical condition: "Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) NL (Completed) BE (Completed) DE (Completed) GR (Completed) HU (Completed) CZ (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001264-28 | Sponsor Protocol Number: P2-IMU-838-COV | Start Date*: 2020-05-28 | |||||||||||
| Sponsor Name:Immunic AG | |||||||||||||
| Full Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Ca... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BG (Completed) RO (Completed) GR (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.